Therapy Areas: Diabetes
Amber Specialty Pharmacy Selected to Dispense TZIELD, a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients Ages eight Years and Older with Stage 2 Type 1 Diabetes
22 November 2022 - - US-based Amber Specialty Pharmacy announces will begin dispensing TZIELD (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes in patients ages eight years and older with Stage 2 T1D, the company said.

Indication for individuals ages eight years and older with Stage 2 T1D is categorized by the presence of two or more T1D-related autoantibodies and abnormal blood sugars.

TZIELD is manufactured by Provention Bio, Inc., a New Jersey-based biopharma company.

Amber Specialty Pharmacy's high touch, infusion-focused service model is designed to support provider offices and appropriate patients with Stage 2 T1D across the country who may be prescribed teplizumab.

The specialty pharmacy has 19 locations ready to care for these patients with their comprehensive services as well as ambulatory and home infusion capabilities.

Amber Specialty Pharmacy, a Hy-Vee, Inc. subsidiary, is in the specialty pharmacy industry with nearly 25 years of experience providing specialized care for persons with chronic, complex medical conditions.

Amber Specialty Pharmacy is accredited by the Utilization Review Accreditation Commission and the Accreditation Commission for Health Care.

Amber Specialty Pharmacy headquarters are located in Omaha, Nebraska, with an additional 18 locations throughout the United States and Puerto Rico.


Related Headlines